The rest of the procedure was the same as described above for GLP-1R immunohistochemistry
, , ,
These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
Anemia may cause weakness, fatigue, dizziness, and a rapid heartbeat
223,224 GLP-1 also inhibits glucagon release from -cells, which is beneficial for reducing blood glucose levels since glucagon promotes hepatic gluconeogenesis
Medicare tends to follow a stricter line, often requiring detailed diagnosis support
